- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Melinda Magyari Explains the Treatment Landscape for Pediatric-Onset MS
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, explains the treatment paradigm for pediatric-onset multiple sclerosis (MS).
Transcript
What does the treatment paradigm for pediatric MS look like today?
That's a good question, but we have the recommendation from the international multiple sclerosis group that disease-modifying treatment should be initiated in children with MS. Of course, the benefit/risk should be also taken into consideration, so the treatment paradigm in most of the countries is escalation therapy, starting with a mild, moderately effective drug in mild and moderate diseases activity. But I see in our registry and also in others that children with highly active disease are initiated with more effective therapies.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
